3SBio Inc  

(Public, NASDAQ:SSRX)   Watch this stock  
Find more results for SSRX
May 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 10.15 - 16.70
Open     -
Vol / Avg. 0.00/149,084.00
Mkt cap 366.10M
P/E 22.58
Div/yield     -
EPS 0.73
Shares     -
Beta 1.46
Inst. own     -

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 30.68% 25.80%
Operating margin 38.22% 34.55%
EBITD margin - 34.48%
Return on average assets 12.38% 16.32%
Return on average equity 14.78% 29.13%
Employees 1,461 -
CDP Score - -


No. 3 A1, Road 10 Shenyang Economy & Technology Development Zone
+86-24-25811820 (Phone)
+86-24-25811821 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


3SBIO INC. is an investment holding company engaged in the development, production, marketing and sale of biopharmaceutical products. The Company primarily focuses on two therapeutic areas: nephrology and oncology. The Company's two core products TPIAO and EPIAO are used in the oncology area to treat chemotherapy-induced thrombocytopenia (CIT) and chemotherapy-induced anemia (CIA), and EPIAO is primarily used in the nephrology area to treat anemia associated with chronic kidney disease (CKD). The Company mainly operates its businesses in the Mainland of China.

Officers and directors

Jing Lou Chairman of the Board, Chief Executive Officer
Age: 49
Bo Tan Chief Financial Officer, Principal Financial and Accounting Officer
Age: 40
Bin Huang Vice President - Human Resources, Director
Age: 51
Ke Li Vice President, Corporate Secretary
Age: 44
Dongmei Su Vice President - Research & Development, Chief Technology Officer, Director
Age: 42
Peiguo Cong Independent Director
Age: 58
Tianruo Pu Independent Director
Age: 46
Moujia Qi Independent Director
Age: 79
Mingde Yu Independent Director
Age: 66